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ABSTRACT 
Purpose To compare graft survival and visual outcomes for endothelial keratoplasty (EK) 
after a first penetrating keratoplasty (PK), with outcomes of repeat PK after a first PK. 
Methods 400 eyes with a second graft (65 EK, 335 PK) performed after failure of a primary 
PK were identified through the Australian Corneal Graft Registry, a national prospectively-
followed cohort. Grafts were performed after January 2008 (follow-up of the second graft 
extending to 6.75 years maximum). Kaplan-Meier graft survival plots were constructed and 
Cox proportional hazards regression was used to identify independent risk factors for graft 
failure. Best corrected Snellen visual acuity (BCVA) at last follow-up was compared with pre-
graft acuity. 
Results Poorer Kaplan-Meier graft survival was observed for PK-EK compared with PK-PK 
(log-rank=29.66, p<0.001). Variables retained in multivariate analysis as significantly 
influencing survival of the second graft included graft type (PK-EK or PK-PK, p<0.001), length 
of survival of the previous PK (global p=0.011), graft era (global p=0.018), occurrence of 
rejection in the second graft (p=0.005) and a history of raised intraocular pressure at any 
time (p=0.048), but not indication for the first graft. BCVA improved in the majority of 
surviving grafts and attainment of 6/12 vision was similar for both PK-EK and PK-PK groups. 
Conclusions Our Registry findings suggest that repeat penetrating keratoplasty may deliver a 
better outcome in terms of graft survival than endokeratoplasty after a failed PK that was 
performed initially for keratoconus or pseudophakic bullous keratopathy. For surviving 
grafts, visual outcomes appear equivalent across groups. 
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INTRODUCTION 
Endothelial keratoplasty (EK), including Descemet stripping endothelial keratoplasty (DSEK) 
or Descemet stripping automated endothelial keratoplasty (DSAEK),[1-3] is increasingly used 
to treat corneal opacification. Despite the potential benefits of EK,[4-6] such procedures fail 
in the early post-operative period at a higher rate than do penetrating grafts.[7, 8] Recent 
practice has seen subsequent EK used as an alternative to repeat full-thickness 
transplantation.[9, 10] This option may be chosen when the corneal stroma and epithelium 
of the previous PK are still relatively healthy, but when endothelial cell loss or failure has led 
to a loss of vision.[4] Because survival of penetrating grafts decreases as the number of 
previous grafts increases,[1, 11] EK following PK is also used in cases for which the original 
indication for PK was keratoconus,[4, 10, 12] in the expectation that graft survival might be 
improved. However, EK has its own risk factors, and repeat EKs still exhibit poorer survival 
than first EKs.[5]  
 The impact of a previous PK on an EK, and the influence of the original pathology on 
the second graft, is not yet fully understood. In addition, uncertainties remain over the 
influence that technical variations exert on graft survival.[4, 9, 13] We analysed the survival 
and visual outcomes of DSEK/DSAEK following previous PK, in comparison to repeat PK, 
performed over the same time period in a national cohort. We further examined the 
comparative survival of PK-EK and PK-PK for common indications for graft. 
 
METHODS 
The Australian Corneal Graft Registry (ACGR) is a national, prospectively-followed cohort of 
over 30,000 corneal transplantations, performed in Australia since May 1985. The 
Institutional Ethics Committee of Flinders University approves the operations of the Registry, 
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which are carried out in accordance with the Declaration of Helsinki. The census date for the 
present analyses was June 2015. Data for this study were contributed by 69 surgeons. 
Records of grafts that matched the following criteria were identified: PK or DSEK or DSAEK 
(both manual and automated dissection techniques acceptable) performed on or after 1st 
January 2008; first repeat (second) graft in the eye; previous PK also registered with the 
ACGR; and follow-up information available within the ACGR. Grafts were categorised into 
two groups: eyes with repeat penetrating keratoplasty (hereafter abbreviated PK-PK), and 
eyes with DSEK/DSAEK following penetrating keratoplasty (PK-EK).  
 
Data collection 
Data collection methods employed by the ACGR are described in detail elsewhere.[7] 
Contributing surgeons listed ocular co-morbidities that might affect graft survival and/or 
visual acuity at graft registration and each follow-up visit thereafter, and at registration also 
specified the desired/anticipated outcome of keratoplasty: improved vision; relief of pain; 
structural repair (tectonic graft); improved cosmesis; any combination of these outcomes. 
 Best-corrected Snellen acuity (BCVA) was recorded at the time of graft and at each 
follow-up. BCVA was measured with prescribed correction (spectacles, contact lens, or both) 
but not with pinhole. The visual outcome of surviving grafts was assessed as the percentage 
of grafts for which BCVA had improved following transplantation, and whether a BCVA of 
6/12 had been achieved at most recent follow-up.  
 
Statistical analyses of graft survival 
Kaplan-Meier survival analysis was performed in SPSS version 22 (IBM Corp, Armonk, NY, 
USA) to compare survival time of the second graft across the two groups (PK-PK; PK-EK), 
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using the log-rank statistic to test statistical significance. Further univariate subgroup 
analyses were performed to compare PK-PK and PK-EK survival for each main indication for 
graft, the influence of length of survival of the previous graft and history of rejection 
episodes in the first graft on survival of the second graft, and the impact of oversizing or 
undersizing the EK in comparison with the previous PK. 
 Variables identified in the 2015 ACGR report[1] as significantly affecting survival of 
PK, DSEK/DSAEK, or both were included in a multivariate Cox-proportional hazards 
regression analysis, clustered by patient, conducted in STATA 11 (Stata-Corp, College Station, 
TX, USA). The length of survival of the previous graft was also included. Allocation of 
continuous variables into categorical groups was performed based on review of the 
published evidence, the distribution of data, and the findings of the 2015 ACGR report.  
The final model included variables with a p-value of p<0.05, with variables eliminated 
in a stepwise manner, beginning with the least significant variable, until all variables 
contributed significantly to the model. For categorical variables, a global test was applied to 
calculate the overall p-value. Tests were conducted to ensure that the assumption of 
proportional hazards was not violated and to identify any time-varying covariates.  
 
RESULTS 
Corneal graft survival and reasons for failure 
We identified 335 PK-PKs and 65 PK-EKs in 400 eyes, performed by 69 surgeons (range 1-44 
grafts), that met the inclusion criteria for analysis. Follow-up ranged from 1 day (for primary 
non-functioning grafts) to 6 years and 9 months. The difference in corneal graft survival 
between these groups was significant (log-rank=29.66, p<0.001), with diminished survival 
found for the PK-EK group compared with the PK-PK group (Figure 1).  
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Failure was reported for 77 PK (23.0%) and 25 EK (38.5%). Primary graft failure was 
reported for three PK (original indication for graft: one keratoconus, one pseudophakic 
bullous keratopathy [PBK], one fungal keratitis) and six EK (original indication for graft: two 
keratoconus, two PBK, one Fuchs endothelial corneal dystrophy [FECD], one penetrating eye 
injury). Graft detachment was reported for seven EK, of which six resolved with treatment, 
and one, performed for previous graft rejection following a penetrating eye injury, 
progressed to primary graft failure. Failures of five EK and 22 PK were attributed to 
irreversible immunological rejection. Other reasons for failure included: endothelial failure 
(11 PK, 7 EK); infection (7PK, 2 EK); corneal ulcer (5 PK); glaucoma (4 PK); trauma (2 PK, 1 EK); 
corneal opacity or scar (2PK, 1 EK); and unknown cause (2 PK). 
 
Subgroup univariate analyses 
A comparison of variables previously shown to influence the survival of PK,[1] EK or both 
revealed significant differences between recipients of PK-PK compared with PK-EK (Table 1). 
Specifically, recipients of PK-PK were more likely (p<0.05) to have been transplanted for 
keratoconus and less likely to have been transplanted for PBK or FECD, more likely to have 
exhibited pre-graft neovascularization, more likely to have undergone surgery in an earlier 
era, and more likely to be phakic, than recipients of PK-EK. The length of survival of the initial 
PK also differed significantly across groups (Chi2=8.08, p=0.044) with 21% of grafts that had a 
repeat PK having previously failed within two years, compared with 11% that went on to 
have a subsequent EK.  
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Table 1 Characteristics of the total cohort 
 Total (n=400) PK-PK (n=335) PK-EK (n=65) P value 
Indication for graft    0.003* 
  Keratoconus 122 (30.5%) 112 (33.4%) 10 (15.4%)  
  Pseudophakic bullous keratopathy  83 (20.8%) 63 (18.8%) 20 (30.8%)  
  Fuchs endothelial corneal dystrophy  62 (15.5%) 46 (13.7%) 16 (24.6%)  
  Other 133 (33.3%) 114 (34.0%) 19 (29.2%)  
Reason for failure of first graft    <0.001* 
  Endothelial failure 152 108 45  
  Rejection 98 78 20  
  Recurrent keratoconus/astigmatism 64 64 0  
  Other 85 85 0  
Rejection episode(s) in first graft 129 (32.3%) 105 (31.3%) 24 (36.9%) 0.378 
Rejection episode(s) in second graft 64 (16.0%) 57 (17.0%) 7 (10.8%) 0.209 
History of raised intraocular pressure 112 (28.6%) 92 (28.1%) 20 (31.3%) 0.614 
Pre-graft inflammation or steroid use 244 (61.8%) 200 (60.6%) 44 (67.7%) 0.283 
Pre-graft neovascularisation 221 (55.3%) 198 (59.1%) 23 (35.4%) <0.001* 
Length of survival of first graft    0.044* 
  Less than 2 years 76 (19.0%) 69 (20.6%) 7 (10.8%)  
  2/3 years 67 (16.8%) 50 (14.9%) 17 (26.2%)  
  4/5 years 47 (11.8%) 37 (11.0%) 10 (15.4%)  
  6 years or longer 210 (52.5%) 179 (53.4%) 31 (47.7%)  
Recipient age group    0.076 
  Under 40 years 31 (7.8%) 28 (8.4%) 3 (4.6%)  
  40 to 49 years 44 (11.0%) 40 (11.9%) 4 (6.2%)  
  50 to 59 years 68 (17.0%) 62 (18.5%) 6 (9.2%)  
  60 to 69 years 73 (18.3%) 56 (16.7%) 17 (26.2%)  
  70 to 79 years 86 (21.5%) 72 (21.5%) 14 (21.5%)  
  80 years or older 98 (24.5%) 77 (23.0%) 21 (32.3%)  
Donor age group    0.495 
  Under 40 years 30 (8.4%) 28 (8.4%) 2 (3.1%)  
  40 to 49 years 25 (6.3%) 23 (6.9%) 2 (3.1%)  
  50 to 59 years 70 (17.5%) 56 (16.7%) 14 (21.4%)  
  60 to 69 years 132 (33.0%) 110 (32.8%) 22 (33.8%)  
  70 to 79 years 97 (24.3%) 81 (24.2%) 16 (24.6%)  
  80 years or older 46 (11.5%) 37 (11.0%) 9 (13.8%)  
Interstate transportation of donor cornea 27 (6.8%) 21 (6.3%) 6 (9.2%) 0.384 
Donor central endothelial cell count density**    0.125 
  <2500 cells/mm² 25 (9.8%) 19 (9.2%) 6 (12.5%)  
  2500 to 2999 cells/mm² 93 (36.6%) 73 (35.4%) 20 (41.7%)  
  3000 to 3499 cells/mm² 115 (45.3 %) 93 (45.1%) 22 (45.8%)  
  3500+ cells/mm² 21 (8.3%) 21 (10.2%) 0 (0.0%)  
Graft size    0.482 
  8 mm or smaller 165 (43.3%) 142 (44.7%) 23 (36.5%)  
  8.25 mm to 8.5 mm 143 (37.5%) 116 (36.5%) 27 (42.9%)  
  8.75 mm or larger 73 (19.2%) 60 (18.9%) 13 (20.6%)  
Graft era**    0.009* 
  2008/2009 146 (37.0%) 131 (39.3%) 15 (24.2%)  
  2010/2011 132 (33.4%) 113 (33.9%) 19 (30.6%)  
  2012/2013 117 (29.6%) 89 (26.7%) 28 (45.2%)  
Surgeon had <25 followed grafts 46 (11.5%) 38 (11.3%) 8 (12.3%) 0.824 
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Eye phakic post-graft 100 (25.0%) 95 (28.4%) 5 (7.7%) <0.001* 
Desired outcome of graft    0.453 
  To improve visual acuity and reduce pain 71 (17.8%) 57 (17.0%) 14 (21.5%)  
  To improve visual acuity, no pain present 277 (69.3%) 231 (69.0%) 46 (70.8%)  
  To reduce pain, no improved vision expected 11 (2.8%) 10 (3.0%) 1 (1.5%)  
  Other reason*** 13 (3.3%) 13 (3.9%) 0 (0.0%)  
  Not specified 28 (7.0%) 24 (7.2%) 4 (6.2%)  
     
 
* p<0.05 ** Grafts from 2014 excluded from analysis (2 PK:PK, 3 PK:EK); Grafts with unknown endothelial cell 
count density excluded from analysis (129 PK:PK, 17 PK:EK);  ***Other reasons included structural repair (12) 
and improved cosmesis (1). 
 
 Graft survival for PK-PK and PK-EK data combined, differed significantly overall based 
on original indication for graft (log-rank=9.65, p=0.022). Further analysis showed that 
diminished graft survival was observed in the PK-EK group compared with the PK-PK group in 
cases for which the original indication was keratoconus (Figure 2a; PK-PK: n=112, PK-EK: 
n=10; log-rank=27.61, p<0.001) or PBK (Figure 2c; PK-PK: n=63, PK-EK: n=20; log-rank=19.67, 
p<0.001), but not FECD (Figure 2b; PK-PK: n=46, PK-EK: n=16; log-rank=1.46, p=0.228) or 
other indication (Figure 2d; PK-PK: n=114, PK-EK: n=19; log-rank=0.85, p=0.356). Exclusion of 
cases in which the repeat graft was performed for an indication other than rejection or 
endothelial failure reduced the log-rank values overall (PK-PK: n=186, PK-EK: n=65; log-
rank=23.43, p<0.001), as well as for keratoconus (PK-PK: n=35, PK-EK: n=10; log-rank=9.72, 
p=0.002) and PBK (PK-PK: n=50, PK-EK: n=20; log-rank=16.34, p<0.001), but the comparisons 
remained significantly different. 
 Length of survival of the previous graft exerted a significant effect on survival of the 
second graft (log rank=23.27, p<0.001), with improved survival in cases in which the first 
graft had survived for at least two years, whereas occurrence of rejection episodes in the 
first graft did not influence survival of the second graft (log-rank=0.42, p=0.515). No 
significant difference was found in survival of PK-EK based on undersizing or oversizing the 
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second graft in comparison with the first (p=0.87). 
 
Multivariate analysis of factors influencing PK-PK and PK-EK graft survival 
A Cox proportional hazards regression model was developed to calculate adjusted risk 
factors for graft failure, controlled for potential confounders. Thirteen grafts were excluded 
because of missing data. The final model incorporated the type of second graft (PK or EK), 
the era over which the second graft was performed, history of raised intraocular pressure at 
any point, whether a rejection episode was reported in the second graft, and length of 
survival of the first PK, chi²=75.23, p<0.001 (Table 2). Survival did not differ significantly 
between grafts that were performed in 2008/09 and 2010/11 (p=0.832). There were no 
significant effects on graft survival amongst the groups in which the original PK had survived 
for two or more years (all p>0.75). 
 
Table 2 Cox proportional hazards regression model  
 n Hazard 
Ratio 
Standard 
Error 
p-Value Global 
p-value 
95% Confidence 
Interval 
Type of second graft       
  PK 325 1.00     
  EK (DSEK/DSAEK) 62 3.67 0.96 <0.001  2.20 – 6.12 
Length of survival of first graft       
  Less than two years 74 1.00   0.011  
  Two or three years 65 0.44 0.15 0.013  0.23 – 0.84 
  Four to five years 46 0.42 0.13 0.006  0.23 – 0.78 
  Six or more years 202 0.46 0.14 0.009  0.26 – 0.82 
Graft Era       
  2012/2013 116 1.00   0.018  
  2010/2011 129 0.50 0.14 0.013  0.29 – 0.87 
  2008/2009 142 0.47 0.14 0.010  0.27 – 0.84 
Rejection episode(s)       
  None 323 1.00     
  At least one 64 1.97 0.47 0.005  1.23 – 3.16 
Raised intraocular pressure in past       
  No 227 1.00     
  Yes 110 1.59 0.37 0.048  1.00 – 2.51 
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Visual outcome 
The desired outcomes from graft are shown in Table 1, with the majority performed to 
improve visual acuity. There were no significant differences in the desired outcome 
(Chi²=3.669, p=0.453), or the pre-graft BCVA (Chi²=2.304, p=0.512), of the two groups. Visual 
outcome (BCVA at last follow-up) for each of four main indications for graft (FECD, PBK, 
keratoconus, other) for grafts performed to improve vision are shown in Table 3. 
Comparative statistical analyses were not possible because of the low number of surviving 
PK-EK grafts with BCVA data provided. However, BCVA improved in the majority of surviving 
grafts. Attainment of 6/12 vision differed by indication for graft, but was similar for both PK-
EK and PK-PK groups. Co-morbid conditions affecting visual acuity at last follow-up were not 
significantly different amongst groups (all p>0.1). The most common co-morbidity was 
glaucoma, which was reported in 14.9% of PK-PK and 7.7% of PK-EK. Grafts performed in 
eyes with glaucoma were less likely to attain 6/12 vision (11.3% vs. 33.6%). 
 
Table 3 Post-operative visual outcome: BCVA at last follow-up in surviving grafts performed to 
improve vision 
Indication, 
graft type 
Surviving Post-graft BCVA 
provided of 
surviving 
Post-graft BCVA 
of 6/12 or 
better 
Pre- and post- 
graft BCVA 
provided 
BCVA improved 
pre- to post-
graft 
FECD      
  PK-PK 33/43 (75.0%) 29/33 (87.9%) 18/29 (62.1%) 29/33 (87.9%) 23/29 (79.3%) 
  PK-EK 10/14 (71.4%) 7/10 (70.0%) 3/7 (42.9%) 7/10 (70.0%) 5/7 (71.4%) 
PBK      
  PK-PK 42/53 (79.2%) 37/42 (88.1%) 3/37 (8.1%) 32/42 (76.2%) 21/32 (65.6%) 
  PK-EK 8/18 (44.4%) 7/8 (87.5%) 2/7 (28.6%) 7/8 (87.5%) 6/7 (85.7%) 
Keratoconus      
  PK-PK 90/102 (88.2%) 88/90 (97.8%) 54/88 (61.4%) 86/90 (95.6%) 72/86 (83.7%) 
  PK-EK 5/10 (50.0%) 3/5 (60.0%) 2/3 (66.7%) 3/5 (60.0%) 3/3 (100.0%) 
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Other      
  PK-PK 64/90 (71.1%) 55/64 (85.9%) 15/55 (27.3%) 55/64 (86.0%) 39/55 (70.9%) 
  PK-EK 14/18 (77.8%) 12/14 (85.7%) 1/12 (8.3%) 11/14 (78.6%) 8/11 (72.7%) 
      
Total      
  PK-PK 229/288 (79.5%) 209/229 (91.3%) 90/209 (43.1%) 202/229 (88.2%) 155/202 (76.7%) 
  PK-EK 37/60 (61.7%) 29/37 (78.4%) 8/29 (27.6%) 28/37 (75.7%) 22/28 (78.6%) 
      
 
 
DISCUSSION 
In our cohort of first repeat grafts following failed PK, graft survival was significantly better in 
eyes that had received a repeat PK, compared with those that had received a subsequent EK. 
The graft detachment rate for DSEK/DSAEK following PK was 10.8%, and the primary graft 
failure rate was 9.2%. These figures fall in the mid-range of those previously reported in 
cohort studies (detachment rate: 6-57%, and primary failure rate: 2-43%).[4-6, 9, 10, 12-18] 
The higher primary graft failure rate for PK-EK compared with PK-PK in our series likely 
reflects the greater early failure rate for EKs generally,[1, 7] possibly as a result of iatrogenic 
trauma. Tarantino-Scherrer et al found a higher graft detachment rate in EK performed 
under previous PK compared to first EK, and documented diminished endothelial cell 
survival following EK for a repeat PK compared with first EK.[19] This may have accounted 
for the high graft failure rate attributed to secondary endothelial failure in our series, but 
because endothelial cell counts at last follow-up were provided for fewer than 5% of grafts 
in our study, we were unable to explore this possibility further. Surgeon experience may also 
have influenced outcomes: data were contributed by 69 surgeons, with varying levels of 
experience. One-fifth of EK procedures were performed by surgeons with fewer than 10 
 12 
prior registered EKs, and thus the primary graft failure rate observed may reflect a learning 
curve amongst surgeons taking up these new procedures. 
A retrospective study by Kitzmann et al, analysing data from grafts in 24 eyes with a 
range of original indications, found no significant difference in graft survival (p=0.504) or 
visual acuity between PK-PK (17 eyes) and PK-EK (7 eyes).[15] However, in a previous large 
comparative cohort study, Ang et al reported results for repeat PK versus EK following failed 
PK in 113 eyes with an initial indication for graft of PBK.[9] Graft survival was better for the 
EKs compared with the repeat PKs (p=0.013), in contrast with our results in a comparable 
but smaller (n=83 eyes) cohort (p<0.001).  
In our multivariate analysis, the length of survival of the first PK was retained as an 
independent variable influencing survival of the second graft (either PK or EK), with first PKs 
surviving for less than two years associated with poorer survival of second grafts. The reason 
is unclear, but is likely to be manifold and may relate to the reason for failure of the first 
graft, including primary graft failure, and eyes in which early rejection episodes were unable 
to be reversed. EK was less likely to be performed in these eyes, possibly indicating a 
surgeon preference for repeat PK in more complex cases. While a history of rejection in the 
original PK was found to influence graft survival significantly in univariate analysis, this 
variable was not retained in the multivariate model. However, consistent with previous 
findings for both first and repeat grafts,[1, 10] rejection episodes in the second graft led to 
diminished graft survival. A factor identified in previous studies as influencing graft survival 
in EK following PK is a history of glaucoma surgery.[4, 10] In our cohort, a history of raised 
intraocular pressure in the grafted eye was associated with an increased hazard ratio of 1.59 
for subsequent failure.  
Although we observed differences in survival between PK-PK and PK-EK in univariate 
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analysis, depending on indication for the original graft, these differences disappeared in 
multivariate analysis: indication for first graft was not an independent risk factor for failure 
of the second graft, irrespective of graft type. All PK-EKs were performed for endothelial 
failure or irreversible rejection of the original graft, whereas those in the PK-PK group 
exhibited a wider range of reasons for failure of the initial graft. However, indication for 
regraft was not retained in multivariate analysis, and when indication for regraft was limited 
to endothelial failure or rejection, the differences in survival remained significant.  
The presence of co-morbid ocular conditions at the time of second graft did not differ 
significantly between PK-PK and PK-EK groups. Similarly, neither pre-graft BCVA nor the 
reported expectation that vision would improve following keratoplasty differed significantly. 
In consequence, it does not appear that our results have been unduly skewed by the 
inclusion of failed PKs that were unsuitable for subsequent EK, or by EK being performed in 
eyes with poor visual prognosis. However, only a randomised and controlled clinical trial in 
which patient groups are truly comparable will be able to provide a definitive answer. 
Comparative outcomes for repeat PK versus EK following PK for keratoconus have 
not been previously reported, although some series include cases in which the original graft 
was performed for keratoconus, amongst other indications.[4, 10, 12] Our findings suggest 
that use of EK in these cases, as in others, results in a greater incidence of graft failure than 
repeat PK, which has previously been shown to exhibit diminished, albeit still acceptable, 
outcomes,[11, 20] although we acknowledge the low number of grafts in our PK-EK group. 
We recognise that many eyes in the PK-PK group exhibited no history of endothelial failure 
or rejection. Better outcomes might thus have been expected in PK-PK eyes. However, 
further analysis including only eyes in which the original PK for keratoconus had failed from 
rejection or endothelial failure still returned a significant result, supporting the need for 
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further investigation of the outcomes from secondary EK in eyes with keratoconus. 
 Previously published case series have reported follow-up ranging from three months 
to five years. Our follow-up is comparable: not all grafts in our cohort had been followed for 
six years (mean follow-up of two years). Kaplan-Meier analysis accounts for censoring of 
data with incomplete follow-up and our practice of analysing survival on a daily basis 
increases reliability. However, because requests for follow-up are made annually, graft 
failure is over-represented in the cohort of followed grafts performed in more recent years. 
Our multivariate model included the era in which the graft was performed, to control for this 
variable.  
 Previous studies have found significantly different survival of EK following failed PK, 
depending on whether the second graft was larger or smaller in diameter than the first; 
however results have been somewhat inconsistent.[4, 9, 13] We found no significant 
difference in survival of PK-EKs, based on undersizing or oversizing the second graft in 
comparison with the first (p=0.87). 
 Graft survival progressively diminishes as the number of previous grafts 
increases.[11] We specifically limited our cohort to first repeat grafts that have a better 
likelihood of survival, a criterion not previously employed in the majority of medium-sized 
case series reported in the literature.[4, 10, 15-17] We cannot extrapolate our findings to the 
likely outcome of grafts performed following multiple previous failures. 
 Endothelial keratoplasty continues to evolve and Descemet membrane endothelial 
keratoplasty (DMEK) is now preferred over DSEK/DSAEK by some surgeons in Australia, as 
elsewhere. However, we have insufficient follow-up of these grafts at present for meaningful 
analysis. 
 Visual outcomes in our cohort were comparable to those published previously, with 
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improvement in vision reported in 63-100% of surviving DSEK following PK, and attainment 
of 6/12 vision achieved in 33-66% of eyes.[5, 6, 10, 13, 14, 16, 17] Our findings suggest that 
visual outcome is related to the original pathology, as are the comparable results for repeat 
PK. 
 The limitations of a registry study include unequal graft follow-up times, the lag-time 
in receiving data on surviving grafts compared with failed grafts, variations (both known and 
unrecognised) between patient subgroups, and inevitable losses to follow-up over time. We 
chose statistical methods (Kaplan-Meier survival and multivariate analyses) to reduce the 
likelihood that these limitations would lead to misleading interpretation of data, but registry 
data are no substitute for prospective, randomised controlled clinical trials. However, while 
such a trial might be desirable to compare outcomes from different forms of keratoplasty, it 
seems unlikely that such a study will be undertaken in the foreseeable future, and a registry 
can provide at least some useful real-world information for surgeons. 
 The practice of performing an endothelial graft in eligible eyes with a failed PK 
continues to increase. Few studies have compared outcomes for these two groups. We 
found that survival for EK following PK was diminished compared to repeat PK, for grafts 
performed over the same time period, and irrespective of the original indication for first 
graft. Factors such as a history of raised intraocular pressure and length of survival of the 
original PK played an important role in survival of the second graft, and might be considered 
when surgery is contemplated. Endothelial grafts have some advantages over full-thickness 
grafts, in that they take less time to heal, involve the use of few (if any) sutures, permit fast 
visual recovery and more consistent refraction, and are less structurally invasive than is 
PK.[4-6] These factors may make a secondary endothelial graft a more attractive and 
appropriate option in some instances than a repeat PK, and surgeons should consider the 
 16 
individual needs and circumstances of their patients when making treatment choices. 
However, repeat penetrating keratoplasty remains a viable treatment option, and may still 
achieve better outcomes in some cases. 
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FIGURE LEGENDS 
 
 
Figure 1 Kaplan-Meier survival plots of repeat penetrating corneal grafts (PK-PK) and 
subsequent endothelial grafts following failed penetrating procedures (PK-EK), performed 
from 2008 onwards. The numbers on the plot represent the number of grafts at risk in each 
stratum. The table shows the numbers at risk in each group at yearly intervals; n/a = not 
applicable. The difference between the curves is significant at P<0.001 (log-rank test). 
Repeat penetrating grafts fared significantly better than PK-EK procedures over the same 
era. 
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Figure 2 Kaplan-Meier survival plots of repeat penetrating corneal grafts (PK-PK) and 
subsequent endothelial grafts following failed penetrating procedures (PK-EK), performed 
from 2008 onwards, for grafts where the indication for graft was a) keratoconus, b) Fuchs 
endothelial dystrophy, c) pseudophakic bullous keratopathy or d) other. The numbers on the 
plots represent the number of grafts at risk in each stratum. The tables show the numbers at 
risk in each group at yearly intervals. The difference between the curves is significant at 
P<0.001 (log-rank test) for a) and c). Repeat penetrating grafts fared significantly better than 
PK-EK procedures over the same era in these cohorts. 
 
